RxDoctor Payments Data

Mickey Thomas

Family · Midland, TXNPI 1225381908

Payments from drug & device makers

$2,334in general payments, 2019–2025

Across 123 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$535
  • Novo Nordisk$390
  • Lilly USA, LLC$317
  • AbbVie$291
  • Boehringer Ingelheim$223
  • Abbott$110
  • plus $469 from 14 others

What the payments were for

  • Food & beverage$2,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,334 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$9,935
Medicare patients
83
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$84,901
MounjaroTirzepatide54$63,987
JardianceEmpagliflozin42$50,582
FarxigaDapagliflozin Propanediol38$46,083
EliquisApixaban33$40,789
Tresiba Flextouch U-200Insulin Degludec16$27,948
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$21,144
JanuviaSitagliptin Phosphate12$16,553
JanumetSitagliptin Phos/Metformin Hcl16$14,170
Albuterol Sulfate HfaAlbuterol Sulfate109$3,873
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$2,928
Gabapentin125$2,483
Levothyroxine Sodium190$1,560
Atorvastatin Calcium249$1,524
Celecoxib52$1,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$390$84,90167 claims
Lilly USA, LLCMounjaro$317$63,98754 claims
Boehringer IngelheimJardiance$223$50,58242 claims
AstraZenecaFarxiga$535$46,08338 claims
PfizerEliquis$79$40,78933 claims
MerckJanuvia, Janumet$13$30,72228 claims
GSKTrelegy Ellipta$47$21,14425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →